Research advances in traditional Chinese medicine in improving nonalcoholic steatohepatitis by regulating the Toll-like receptor 4/nuclear factor-kappa B signaling pathway

Gege TIAN; Enrui XIA; Suyan ZHANG; Shunzhen ZHAGN; Furong XU

doi:10.3969/j.issn.1001-5256.2021.12.047

Volume 37 Issue 12

Dec. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(12): 2957-2962

PDF( 1998 KB)

Research advances in traditional Chinese medicine in improving nonalcoholic steatohepatitis by regulating the Toll-like receptor 4/nuclear factor-kappa B signaling pathway

DOI: 10.3969/j.issn.1001-5256.2021.12.047

School of Traditional Chinese Medicine, Yunnan University of Traditional Chinese Medicine, Kunming 650000, China

Research funding:

National Natural Science Foundation of China (81760818);

Key Laboratory of Microcosmic Syndrome Differentiation of TCM Syndrome in Yunnan Province (20190720);

Joint Special Project of Traditional Chinese Medicine of Yunnan Provincial Science and Technology Department (2018FF001(-042))

Received Date: 2021-05-22
Accepted Date: 2021-07-21
Published Date: 2021-12-20

Abstract

Abstract

Nonalcoholic steatohepatitis (NASH) is a serious type of nonalcoholic fatty liver disease (NAFLD) and can develop into life-threatening liver cirrhosis and liver cancer. Toll-like receptor 4 (TLR4) is a type of pattern recognition receptor in innate immunity, and after being activated, it can trigger a cascade reaction and activate nuclear factor-κB (NF-κB) which mediates inflammatory response. The TLR4/NF-κB signaling pathway is a classic inflammatory pathway. In clinical practice, traditional Chinese medicine has achieved a good effect in the treatment of NASH, and the TLR4/NF-κB signaling pathway is one of the approaches for traditional Chinese medicine to treat NASH. By searching the relevant literature, this article summarizes the active components and compounds of traditional Chinese medicine that can regulate the TLR4/NF-κB signaling pathway to alleviate NASH, so as to provide ideas for future research and medication.
- Nonalcoholic Steatohepatitis,
- Toll-Like Receptor 4,
- NF-kappa B,
- Drugs, Chinese Herbal

FullText(HTML)

References(48)

References

[1]	BUZZETTI E, PINZANI M, TSOCHATZIS EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)[J]. Metabolism, 2016, 65(8): 1038-1048. DOI: 10.1016/j.metabol.2015.12.012.
[2]	SAAD ZA, KHODEER DM, ZAITONE SA, et al. Exenatide ameliorates experimental non-alcoholic fatty liver in rats via suppression of toll-like receptor 4/NFκB signaling: Comparison to metformin[J]. Life Sci, 2020, 253: 117725. DOI: 10.1016/j.lfs.2020.117725.
[3]	FITZGERALD KA, KAGAN JC. Toll-like receptors and the control of immunity[J]. Cell, 2020, 180(6): 1044-1066. DOI: 10.1016/j.cell.2020.02.041.
[4]	WANG Y, ZHANG S, LI H, et al. Small-molecule modulators of toll-like receptors[J]. Acc Chem Res, 2020, 53(5): 1046-1055. DOI: 10.1021/acs.accounts.9b00631.
[5]	FUSELLA F, SECLÌ L, CANNATA C, et al. The one thousand and one chaperones of the NF-κB pathway[J]. Cell Mol Life Sci, 2020, 77(12): 2275-2288. DOI: 10.1007/s00018-019-03402-z.
[6]	VALIZADEH A, MAJIDINIA M, SAMADI-KAFIL H, et al. The roles of signaling pathways in liver repair and regeneration[J]. J Cell Physiol, 2019. DOI: 10.1002/jcp.28336.
[7]	CSAK T, VELAYUDHAM A, HRITZ I, et al. Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice[J]. Am J Physiol Gastrointest Liver Physiol, 2011, 300(3): G433-G441. DOI: 10.1152/ajpgi.00163.2009.
[8]	CHEN SN, TAN Y, XIAO XC, et al. Effect of TLR4 gene knockout on acute liver injury in septic mice[J]. J Pract Med, 2020, 36(11): 1425-1428. DOI: 10.3969/j.issn.1006-5725.2020.11.004. 陈赛男, 谭迎, 肖筱婵, 等. TLR4基因敲除对脓毒症小鼠急性肝损伤的影响[J]. 实用医学杂志, 2020, 36(11): 1425-1428. DOI: 10.3969/j.issn.1006-5725.2020.11.004.
[9]	XU HC, GAO Y, MENG YN, et al. Correlation between TLR4 gene and its methylation level in non-alcoholic steatohepatitis rats[J]. Tianjin Med J, 2020, 48(7): 625-629. DOI: 10.11958/20193587. 徐慧超, 高艳, 孟雅楠, 等. 非酒精性脂肪性肝炎大鼠TLR4基因及其甲基化水平的相关性研究[J]. 天津医药, 2020, 48(7): 625-629. DOI: 10.11958/20193587.
[10]	SWANTEK JL, TSEN MF, COBB MH, et al. IL-1 receptor-associated kinase modulates host responsiveness to endotoxin[J]. J Immunol, 2000, 164(8): 4301-4306. DOI: 10.4049/jimmunol.164.8.4301.
[11]	SONG IJ, YANG YM, INOKUCHI-SHIMIZU S, et al. The contribution of toll-like receptor signaling to the development of liver fibrosis and cancer in hepatocyte-specific TAK1-deleted mice[J]. Int J Cancer, 2018, 142(1): 81-91. DOI: 10.1002/ijc.31029.
[12]	HE Q, ZENG J, YAO K, et al. Long-term subcutaneous injection of lipopolysaccharides and high-fat diet induced non-alcoholic fatty liver disease through IKKε/ NF-κB signaling[J]. Biochem Biophys Res Commun, 2020, 532(3): 362-369. DOI: 10.1016/j.bbrc.2020.08.036.
[13]	CHEN CY, KAO CL, LIU CM. The cancer prevention, anti-inflammatory and anti-oxidation of bioactive phytochemicals targeting the TLR4 signaling pathway[J]. Int J Mol Sci, 2018, 19(9): 2729. DOI: 10.3390/ijms19092729.
[14]	MITCHELL JP, CARMODY RJ. NF-κB and the transcriptional control of inflammation[J]. Int Rev Cell Mol Biol, 2018, 335: 41-84. DOI: 10.1016/bs.ircmb.2017.07.007.
[15]	YAO Q, LI S, LI X, et al. Myricetin modulates macrophage polarization and mitigates liver inflammation and fibrosis in a murine model of nonalcoholic steatohepatitis[J]. Front Med (Lausanne), 2020, 7: 71. DOI: 10.3389/fmed.2020.00071.
[16]	MARCOLIN E, SAN-MIGUEL B, VALLEJO D, et al. Quercetin treatment ameliorates inflammation and fibrosis in mice with nonalcoholic steatohepatitis[J]. J Nutr, 2012, 142(10): 1821-1828. DOI: 10.3945/jn.112.165274.
[17]	LIU J, YUAN Y, GONG X, et al. Baicalin and its nanoliposomes ameliorates nonalcoholic fatty liver disease via suppression of TLR4 signaling cascade in mice[J]. Int Immunopharmacol, 2020, 80: 106208. DOI: 10.1016/j.intimp.2020.106208.
[18]	ZHOU GY, YI YX, JIN LX, et al. The protective effect of juglanin on fructose-induced hepatitis by inhibiting inflammation and apoptosis through TLR4 and JAK2/STAT3 signaling pathways in fructose-fed rats[J]. Biomed Pharmacother, 2016, 81: 318-328. DOI: 10.1016/j.biopha.2016.04.013.
[19]	ZHANG KF, JIN L. Protective effect and mechanism of dicliptera chinensis polysaccharides on non-alcoholic fatty liver disease in rats based on PPAR-γ and TLR-4/NF-κB signaling pathway[J]. Pharmacol Clin Chin Mater Clin Med, 2019, 35(4): 103-107. DOI: 10.13412/j.cnki.zyyl.2019.04.020. 张可锋, 晋玲. 基于PPAR-γ和TLR-4/NF-κB信号通路研究狗肝菜多糖对非酒精性脂肪性肝大鼠的保护作用机制[J]. 中药药理与临床, 2019, 35(4): 103-107. DOI: 10.13412/j.cnki.zyyl.2019.04.020.
[20]	WANG JQ, LI J, ZOU YH, et al. Therapeutic effects of Total Flavonoids of Litsea Coreana leve on nonalcoholic steatohepatitis and its partly mechanisms of action[J]. Chin Pharmacol Bull, 2012, 28(3): 412-416. DOI: 10.3969/j.issn.1001-1978.2012.03.026. 王建青, 李俊, 邹宇宏, 等. 豹皮樟总黄酮对非酒精性脂肪性肝炎治疗作用及部分机制[J]. 中国药理学通报, 2012, 28(3): 412-416. DOI: 10.3969/j.issn.1001-1978.2012.03.026.
[21]	DONG ZC, GAO Q, MAO JN. The regulatory effect of bilobalide on hepatic fibrosis of nonalcoholic steatohepatitis rat via TLR4/TAK1/NF-κB signaling pathway[J]. J Shenyang Pharm Univ, 2019, 36(8): 716-722. DOI: 10.14066/j.cnki.cn21-1349/r.2019.08.012. 董志超, 高琦, 毛建娜. 白果内酯通过TLR4/TAK1/NF-κB通路对非酒精性脂肪肝炎大鼠模型肝纤维化的调控作用[J]. 沈阳药科大学学报, 2019, 36(8): 716-722. DOI: 10.14066/j.cnki.cn21-1349/r.2019.08.012.
[22]	BAI JH, LIANG ZQ, ZHAO RH, et al. Effect of artesunate on the expression of TLR4 and MyD88 in mice with non-alcoholic fatty liver disease[J]. Acta Univ Med Anhui, 2017, 52(10): 1468-1471. DOI: 10.19405/j.cnki.issn1000-1492.2017.10.011. 白纪红, 梁志清, 赵日红, 等. 青蒿琥酯对非酒精性脂肪肝小鼠肝脏TLR4及MyD88表达的影响[J]. 安徽医科大学学报, 2017, 52(10): 1468-1471. DOI: 10.19405/j.cnki.issn1000-1492.2017.10.011.
[23]	LIU BF, ZHOU DS, LIANG ZQ, et al. The effects of artesunate on the expression of NF-κB、TNF-αin liver tissues of mice with nonalcoholic fatty liver disease[J]. Pharmacol Clin Chin Mater Clin Med, 2014, 30(5): 23-26. DOI: 10.13412/j.cnki.zyyl.2014.05.008. 刘博峰, 周冬生, 梁志清, 等. 青蒿琥酯对非酒精性脂肪肝小鼠肝组织NF-κB、TNF-α的影响[J]. 中药药理与临床, 2014, 30(5): 23-26. DOI: 10.13412/j.cnki.zyyl.2014.05.008.
[24]	LIU YL, ZHANG QZ, WANG YR, et al. Astragaloside IV improves high-fat diet-induced hepatic steatosis in nonalcoholic fatty liver disease rats by regulating inflammatory factors level via TLR4/NF-κB signaling pathway[J]. Front Pharmacol, 2020, 11: 605064. DOI: 10.3389/fphar.2020.605064.
[25]	SHEN S, WANG K, ZHI Y, et al. Gypenosides improves nonalcoholic fatty liver disease induced by high-fat diet induced through regulating LPS/TLR4 signaling pathway[J]. Cell Cycle, 2020, 19(22): 3042-3053. DOI: 10.1080/15384101.2020.1829800.
[26]	CHEN C, FENG CS, ZHANG WL, et al. Effects of shikonin on nonalcoholic steatohepatitis and its molecular mechanism[J]. Immunol J, 2021, 37(1): 60-66. DOI: 10.13431/j.cnki.immunol.j.20210009. 陈超, 冯长松, 张伟丽, 等. 紫草素对非酒精性脂肪性肝炎的影响及分子机制研究[J]. 免疫学杂志, 2021, 37(1): 60-66. DOI: 10.13431/j.cnki.immunol.j.20210009.
[27]	ZHAO ZM, WU JZ, YAO Z, et al. Effects of Cassia glycosides on the rats with non-alcoholic fatty liver disease through Toll-like receptor 4 and nuclear factor-κB[J]. Chin J Clin Pharmacol, 2019, 35(22): 2863-2867. DOI: 10.13699/j.cnki.1001-6821.2019.22.024. 赵梓铭, 武俊紫, 姚政, 等. 决明子蒽醌苷通过降低Toll样受体4和核因子-κB的表达对非酒精性脂肪肝病大鼠的影响[J]. 中国临床药理学杂志, 2019, 35(22): 2863-2867. DOI: 10.13699/j.cnki.1001-6821.2019.22.024.
[28]	LYU YL, LIU CC, LIU H, et al. Effects of rhein on TLR4 signaling pathway in NAFLD rats[J]. Chin J Health Lab Technol, 2018, 28(21): 2580-2584. https://www.cnki.com.cn/Article/CJFDTOTAL-ZWJZ201821007.htm 吕媛琳, 刘晨晨, 刘慧, 等. 大黄酸对非酒精性脂肪性肝病大鼠TLR4信号通路的影响[J]. 中国卫生检验杂志, 2018, 28(21): 2580-2584. https://www.cnki.com.cn/Article/CJFDTOTAL-ZWJZ201821007.htm
[29]	WANG L, JIA Z, WANG B, et al. Berberine inhibits liver damage in rats with non-alcoholic fatty liver disease by regulating TLR4/MyD88/NF-κB pathway[J]. Turk J Gastroenterol, 2020, 31(12): 902-909. DOI: 10.5152/tjg.2020.19568.
[30]	SONG CY, SHI J, ZENG X, et al. Sophocarpine alleviates hepatocyte steatosis through activating AMPK signaling pathway[J]. Toxicol In Vitro, 2013, 27(3): 1065-1071. DOI: 10.1016/j.tiv.2013.01.020.
[31]	SONG CY, ZENG X, WANG Y, et al. Sophocarpine attenuates toll-like receptor 4 in steatotic hepatocytes to suppress pro-inflammatory cytokines synthesis[J]. J Gastroenterol Hepatol, 2015, 30(2): 405-412. DOI: 10.1111/jgh.12691.
[32]	FENG D, ZOU J, SU D, et al. Curcumin prevents high-fat diet-induced hepatic steatosis in ApoE(-/-) mice by improving intestinal barrier function and reducing endotoxin and liver TLR4/NF-κB inflammation[J]. Nutr Metab (Lond), 2019, 16: 79. DOI: 10.1186/s12986-019-0410-3.
[33]	LIN P, LU J, WANG Y, et al. Naturally occurring stilbenoid TSG reverses non-alcoholic fatty liver diseases via gut-liver axis[J]. PLoS One, 2015, 10(10): e0140346. DOI: 10.1371/journal.pone.0140346.
[34]	MA JM, GAO LL, ZHANG MW, et al. Role and mechanism of Lycium barbarum polysaccharide combined with aerobic exercise in improving nonalcoholic Steatohepatitis in rats[J]. J Clin Hepatol, 2021, 37(6): 1348-1353. DOI: 10.3969/j.issn. 1001-5256.2021.06.026. 马佳敏, 高璐璐, 张梦伟, 等. 枸杞多糖联合有氧运动对非酒精性脂肪肝炎大鼠模型的改善作用及其机制研究[J]. 临床肝胆病杂志, 2021, 37(6): 1348-1353. DOI: 10.3969/j.issn. 1001-5256.2021.06.026.
[35]	LIU B, DENG X, JIANG Q, et al. Scoparone alleviates inflammation, apoptosis and fibrosis of non-alcoholic steatohepatitis by suppressing the TLR4/NF-κB signaling pathway in mice[J]. Int Immunopharmacol, 2019, 75: 105797. DOI: 10.1016/j.intimp.2019.105797.
[36]	LU S, ZHANG T, GU W, et al. Volatile oil of amomum villosum inhibits nonalcoholic fatty liver disease via the gut-liver axis[J]. Biomed Res Int, 2018, 2018: 3589874. DOI: 10.1155/2018/3589874.
[37]	SHU X, WANG M, XU H, et al. Extracts of salvia-nelumbinis naturalis ameliorate nonalcoholic steatohepatitis via inhibiting gut-derived endotoxin mediated TLR4/NF-κB activation[J]. Evid Based Complement Alternat Med, 2017, 2017: 9208314. DOI: 10.1155/2017/9208314.
[38]	LI ZG, JIANG HX, JIAO YT, et al. Literary analysis on distribution of traditional Chinese medicine syndromes of non-alcoholic fatty liver disease[J]. Chin J Tradit Chin Med Pharm, 2017, 32(10): 4713-4715. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201710106.htm 李志国, 姜韩雪, 焦云涛, 等. 非酒精性脂肪性肝病中医证型分布的文献分析[J]. 中华中医药杂志, 2017, 32(10): 4713-4715. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201710106.htm
[39]	ZHANG SS, LI JX. Expert consensus on TCM diagnosis and treatment of nonalcoholic fatty liver disease (2017)[J]. J Clin Hepatol, 2017, 33(12): 2270-2274. DOI: 10.3969/j.issn.1001-5256.2017.12.002. 张声生, 李军祥. 非酒精性脂肪性肝病中医诊疗专家共识意见(2017)[J]. 临床肝胆病杂志, 2017, 33(12): 2270-2274. DOI: 10.3969/j.issn.1001-5256.2017.12.002.
[40]	GAO GY, LI S, XUE JD, et al. Traditional Chinese medicine syndrome types and syndrome elements of nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2021, 37(1): 89-93. DOI: 10.3969/j.issn.1001-5256.2021.01.018. 高改娅, 李莎, 薛敬东, 等. 非酒精性脂肪性肝病中医证型及证素研究[J]. 临床肝胆病杂志, 2021, 37(1): 89-93. DOI: 10.3969/j.issn.1001-5256.2021.01.018.
[41]	TRIPATHI A, DEBELIUS J, BRENNER DA, et al. The gut-liver axis and the intersection with the microbiome[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(7): 397-411. DOI: 10.1038/s41575-018-0011-z.
[42]	ZHANG Y, ZHU X, ZHENG D, et al. Effects of qutan huoxue formula on the SOCS1/TLR4 signaling pathway in NASH model mice[J]. Evid Based Complement Alternat Med, 2020, 2020: 1570918. DOI: 10.1155/2020/1570918.
[43]	MA W, YANG JY, AN L, et al. Mechanism of Fuzilizhong decoction alleviating inflammatory damage of rats with non-alcoholic fatty liver disease[J]. Chin J pathophysiol, 2020, 36(12): 2258-2263. DOI: 10.3969/j.issn.1000-4718.2020.12.019. 马威, 杨家耀, 安柳, 等. 附子理中汤减轻非酒精性脂肪肝大鼠炎症损伤的机制研究[J]. 中国病理生理杂志, 2020, 36(12): 2258-2263. DOI: 10.3969/j.issn.1000-4718.2020.12.019.
[44]	GUO YY, SUN XQ, FANG J, et al. Effect of modified Zexietang on expression of proteins related to inflammatory pathway in NAFLD rat[J]. Chin J Exp Tradit Med Form, 2017, 23(5): 90-94. DOI: 10.13422/j.cnki.syfjx.2017050090. 郭雨雅, 孙晓琦, 方晶, 等. 加味泽泻汤对NAFLD大鼠肝脏炎症信号通路相关蛋白表达的影响[J]. 中国实验方剂学杂志, 2017, 23(5): 90-94. DOI: 10.13422/j.cnki.syfjx.2017050090.
[45]	ZHANG HO, LIN QX, XU MJ, et al. Study on the influence of Jianpiqinghuafang on nonalcoholic fatty liver disease[J]. Chin J Integr Tradit West Med on Liver, 2019, 29(2): 163-166. DOI: 10.3969/j.issn.1005-0264.2019.02.021. 张海鸥, 林清香, 许梦君, 等. 健脾清化饮对非酒精性脂肪性肝病大鼠TLR4/NF-κB/TNF-α信号通路的影响[J]. 中西医结合肝病杂志, 2019, 29(2): 163-166. DOI: 10.3969/j.issn.1005-0264.2019.02.021.
[46]	LIU J, ZHUANG ZJ, TIAN J, et al. Effect of compound Zhajin granule on Toll-like receptor 4 signaling pathway in nonalcoholic steatohepatitis mice[J]. Chin J Integr Tradit West Med on Liver, 2016, 36(4): 460-465. DOI: 10.7661/CJIM.2016.04.0460. 刘静, 庄振杰, 田静, 等. 复方楂金颗粒对NASH小鼠肝脏内TLR4信号通路的影响[J]. 中国中西医结合杂志, 2016, 36(4): 460-465. DOI: 10.7661/CJIM.2016.04.0460.
[47]	XIANG J, SHI JP, CHEN HJ, et al. Effect of complex prescription Zhajin drug granules on expression of Toll-like receptor 4 in rats with NASH[J]. Chin Arch Tradit Chin Med, 2017, 35(7): 1719-1723. DOI: 10.13193/j.issn.1673-7717.2017.07.023. 向晶, 施军平, 陈海君, 等. 复方楂金颗粒剂对非酒精性脂肪性肝炎大鼠Toll样受体4的影响[J]. 中华中医药学刊, 2017, 35(7): 1719-1723. DOI: 10.13193/j.issn.1673-7717.2017.07.023.
[48]	YANG JM, SUN Y, WANG M, et al. Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease[J]. World J Gastroenterol, 2019, 25(34): 5105-5119. DOI: 10.3748/wjg.v25.i34.5105.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1) / Tables(2)

Get Citation

PDF

XML

Article Metrics

Article views (1008) PDF downloads(54)

Research advances in traditional Chinese medicine in improving nonalcoholic steatohepatitis by regulating the Toll-like receptor 4/nuclear factor-kappa B signaling pathway

DOI: 10.3969/j.issn.1001-5256.2021.12.047

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Research advances in traditional Chinese medicine in improving nonalcoholic steatohepatitis by regulating the Toll-like receptor 4/nuclear factor-kappa B signaling pathway

DOI: 10.3969/j.issn.1001-5256.2021.12.047

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content